19
miR-494 inhibitor, for the treatment of retinal disease
Stanford University
Gene therapy
Ophthalmology
Target Identification or Validation
Epiretinal membranes (ERMs) are conditions where a very thin layer of scar tissue forms on the surface of the retina in an area that is responsible for our sharpest vision. A team of Stanford researchers have developed a non-surgical therapeutic strategy for treating or preventing epiretinal membranes or other eye diseases by inhibiting microRNA (miRNA). MicroRNAs are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. The inventors have validated miR-494-3p as the only miRNA expressed at significantly greater levels in ERM
PCT-US2019-024090
